Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany
Open Access
- 5 May 2022
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 29 (7) , 536-542
Abstract
In 2014, an analysis was conducted to evaluate the hepatitis C virus (HCV) epidemiology and disease burden in Germany. Since then, there have been considerable developments in HCV management such as the implementation of direct acting antivirals. The aim of this analysis was to assess the recent data available for Germany, establish an updated 2020 HCV prevalence and cascade of care and evaluate the impact of what‐if scenarios on the future burden of disease using modelling analysis. A dynamic Markov model was used to forecast the HCV disease burden in Germany. Model inputs were retrieved through literature review, unpublished sources and expert input. Next, three “what‐if” scenarios were developed to evaluate the status quo, COVID‐19 pandemic, and steps needed to achieve the WHO targets for elimination. At the beginning of 2020, there were 189,000 (95% UI: 76,700–295,000) viremic infections in Germany, a decline of more than 85,000 viremic infections since 2012. Annual treatment starts went down since 2015. Compared with 2019, the COVID‐19 pandemic resulted in a further 11% decline in 2020. If this continues for two years, it could result in 110 excess HCC cases and 200 excess liver related deaths by 2030. To achieve the WHO targets, 81,200 people need to be diagnosed, with 118,600 initiated on treatment by 2030. This could also avert 1,020 deaths and 720 HCC cases between 2021 and 2030. Germany has made strides towards HCV elimination, but more efforts are needed to achieve the WHO targets by 2030.Keywords
Funding Information
- Gilead Sciences
This publication has 20 references indexed in Scilit:
- Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment RegimensClinical Gastroenterology and Hepatology, 2019
- Hepatitis-C-Virus Seroprävalenz und Abhängigkeit vom Herkunftsland bei Flüchtlingen in Rheinland-Pfalz/Deutschland im Jahr 2015Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2018
- S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“Zeitschrift für Gastroenterologie, 2018
- Seroprevalence of antibodies and antigens against hepatitis A–E viruses in refugees and asylum seekers in Germany in 2015European Journal of Gastroenterology & Hepatology, 2017
- Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral centerJournal of Gastroenterology and Hepatology, 2017
- Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenariosJournal of Hepatology, 2015
- Strategies to manage hepatitisCvirus (HCV) disease burdenJournal of Viral Hepatitis, 2014
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of Viral Hepatitis, 2014
- Historical epidemiology of hepatitis C virus (HCV) in selected countriesJournal of Viral Hepatitis, 2014
- Die Seroepidemiologie der Hepatitis A, B und C in DeutschlandBundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2013